Skip to main content
SpringerLink
Log in

Rheumatoid Arthritis and Gastrointestinal Tract Lesions (NSAID Ulcers, Amyloidosis)

  • Chapter
  • First Online:
Gastrointestinal and Hepatic Manifestations of Rheumatic Diseases

Abstract

This chapter discusses the relationship of rheumatoid arthritis (RA) to nonsteroidal anti-inflammatory drug (NSAID)-associated ulcers and intestinal amyloidosis, both of which are gastrointestinal tract lesions. NSAID ulcers associated with RA are not as common as they once were. There are three reasons for this. First, the role of NSAIDs in rheumatoid arthritis treatment has changed. Second, NSAIDs less damaging to the intestines have become available. Third, there is now much greater awareness of NSAID ulcers. Changes in the role of NSAIDs are attributable to less and shorter-term use of NSAIDs, which were previously used widely and for a long time to treat inflammation, thanks to the appearance of antirheumatic drugs and biological products. NSAIDs less damaging to the intestines that are now available include NSAIDs that selectively inhibit cyclooxygenase (COX) 2. These were developed after it was found that COX-1, to which conventional NSAIDs bind to reduce inflammation and pain, helps protect the stomach lining. Finally, with greater awareness of the gastrointestinal damage NSAIDs cause has come greater focus on preventing ulcers. Health insurance now covers prophylactic proton pump inhibitors, which are widely used to treat gastric ulcers, for high-risk patients. The result has been a significant drop in ulcers.

Almost all amyloidosis associated with RA is AA amyloidosis, which is known as secondary or reactive amyloidosis. As these names suggest, amyloidosis occurs secondarily during the course of RA and other chronic inflammatory diseases. Progress in RA treatment has made long-term control of inflammation possible in more patients and, consequently, less amyloidosis occurring in association with the disease. Even so, patients treated for RA should undergo regular screening for AA amyloidosis and be checked for clinical symptoms so that AA amyloidosis can be detected early.

This chapter describes in detail RA-associated NSAID ulcers and amyloidosis, which, although now less common, remain as risks to RA patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625–39.

    Article  CAS  Google Scholar 

  2. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509.

    Article  CAS  PubMed  Google Scholar 

  3. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231(25):232–5.

    Article  CAS  PubMed  Google Scholar 

  4. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A. 1991;88(7):2692–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem. 1991;266(20):12866–72.

    CAS  PubMed  Google Scholar 

  6. Sakamoto C. Roles of COX-1 and COX-2 in gastrointestinal pathophysiology. J Gastroenterol. 1998;33(5):618–24.

    Article  CAS  PubMed  Google Scholar 

  7. Sakamoto C, Kawai T, Nakamura S, Sugioka T, Tabira J. Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: a placebo-controlled, double-blind 2-week study. Aliment Pharmacol Ther. 2013;37(3):346–54.

    Article  CAS  PubMed  Google Scholar 

  8. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286(8):954–9.

    Article  CAS  PubMed  Google Scholar 

  9. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation. 2000;102(8):840–5.

    Article  CAS  PubMed  Google Scholar 

  10. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005;330(7504):1366.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Solomon DH, Glynn RJ, Rothman KJ, Schneeweiss S, Setoguchi S, Mogun H, Avorn J, Sturmer T. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum. 2008;59(8):1097–104.

    Article  PubMed  PubMed Central  Google Scholar 

  12. The Japanese Society of Gastroenterology. Evidence-based clinical practice guidelines for peptic ulcer disease 2015. 2nd ed; 2015.

    Google Scholar 

  13. Masso Gonzalez EL, Patrignani P, Tacconelli S, Garcia Rodriguez LA. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010;62(6):1592–601.

    Article  PubMed  Google Scholar 

  14. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, McGowan J. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002;(4):CD002296.

    Google Scholar 

  15. Sakamoto C, Sugano K, Ota S, Sakaki N, Takahashi S, Yoshida Y, Tsukui T, Osawa H, Sakurai Y, Yoshino J, Mizokami Y, Mine T, Arakawa T, Kuwayama H, Saigenji K, Yakabi K, Chiba T, Shimosegawa T, Sheehan JE, Perez-Gutthann S, Yamaguchi T, Kaufman DW, Sato T, Kubota K, Terano A. Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol. 2006;62(9):765–72.

    Article  CAS  PubMed  Google Scholar 

  16. Lanas A, Garcia-Rodriguez LA, Arroyo MT, Gomollon F, Feu F, Gonzalez-Perez A, Zapata E, Bastida G, Rodrigo L, Santolaria S, Guell M, de Argila CM, Quintero E, Borda F, Pique JM, Asociacion Espanola de G. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006;55(12):1731–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160(14):2093–9.

    Article  CAS  PubMed  Google Scholar 

  18. Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, Eriksson B, Appelman-Eszczuk S, Langstrom G, Naesdal J, Serrano P, Singh M, Skelly MM, Hawkey CJ. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther. 2005;22(9):795–801.

    Article  CAS  PubMed  Google Scholar 

  19. Kamada T, Haruma K, Murao T, et al. Clinical features and treatment of NSAID-related gastric ulcers—association with H. Pylori infection. Stomach Intestine (Tokyo). 2017;52(7):892–9.

    Google Scholar 

  20. Ikezawa K, Mizokami Y, Sugiyama H, et al. Diagnosis and prevention of NSAIDs-induced (including LDA) upper gatrointestinal mucosal injury. Stomach Intestine (Tokyo). 2016;51(4):432–41.

    Google Scholar 

  21. Sigthorsson G, Simpson RJ, Walley M, Anthony A, Foster R, Hotz-Behoftsitz C, Palizban A, Pombo J, Watts J, Morham SG, Bjarnason I. COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology. 2002;122(7):1913–23.

    Article  CAS  PubMed  Google Scholar 

  22. Syer SD, Blackler RW, Martin R, de Palma G, Rossi L, Verdu E, Bercik P, Surette MG, Aucouturier A, Langella P, Wallace JL. NSAID enteropathy and bacteria: a complicated relationship. J Gastroenterol. 2015;50(4):387–93.

    Article  CAS  PubMed  Google Scholar 

  23. Watanabe T, Tanigawa T, Nadatani Y, Nagami Y, Sugimori S, Okazaki H, Yamagami H, Watanabe K, Tominaga K, Fujiwara Y, Koike T, Arakawa T. Risk factors for severe nonsteroidal anti-inflammatory drug-induced small intestinal damage. Dig Liver Dis. 2013;45(5):390–5.

    Article  CAS  PubMed  Google Scholar 

  24. Wallace JL. Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. World J Gastroenterol. 2013;19(12):1861–76.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Nakamura S, Jinno Y, Matsumoto T, et al. A clinical study of NSAID suppository-induced rectal lesions. Stomach Intestine (Tokyo). 2007;42(12):1730–8.

    Google Scholar 

  26. Kurahara K, Matsumoto T, Yao T, et al. Clinical and endoscopic features of nonsteroidal anti-inflammatory drug-induced Colopathy. Stomach Intestine (Tokyo). 2007;42(12):1739–49.

    Google Scholar 

  27. Matsumoto T, Iida M. Clinical and endoscopic features in patients with nonsteroidal anti-inflammatory drug-induced Colopathy. Stomach Intestine (Tokyo). 2000;35(9):1147–58.

    Google Scholar 

  28. Torisu T, Okamoto Y, Washio E, et al. Pathogenesis and endoscopic features of nonsteroidal anti-inflammatory drugs (NSAIDs)-induced lower intestinal damage. Stomach Intestine (Tokyo). 2016;51(4):442–9.

    Google Scholar 

  29. Fujimori S, Ensaka Y, Maki K, et al. NSAID induced small intestinal lesions. Stomach Intestine (Tokyo). 2011;46(2):128–36.

    Google Scholar 

  30. Matsumoto T, Nakamura S, Esaki M, et al. Enteroscopic features of chronic nonspecific multiple ulcers of the small intestine: comparison with nonsteroidal anti-inflammatory drug induced Enteropathy. Stomach Intestine (Tokyo). 2006;41(12):1637–48.

    Google Scholar 

  31. Taguchi H, Yamamoto H, Hayashi Y, et al. Non-steroidal anti-inflammatory drug (NSAID) induced lesions in the small intestine. Stomach Intestine (Tokyo). 2007;41(12):1721–9.

    Google Scholar 

  32. Goldstein NS, Cinenza AN. The histopathology of nonsteroidal anti-inflammatory drug-associated colitis. Am J Clin Pathol. 1998;110(5):622–8.

    Article  CAS  PubMed  Google Scholar 

  33. Jaszewski R, Graham DY, Stromatt SC. Treatment of nonsteroidal antiinflammatory drug-induced gastric ulcers with misoprostol. A double-blind multicenter study. Dig Dis Sci. 1992;37(12):1820–4.

    Article  CAS  PubMed  Google Scholar 

  34. Tildesley G, Ehsanullah RS, Wood JR. Ranitidine in the treatment of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drugs. Br J Rheumatol. 1993;32(6):474–8.

    Article  CAS  PubMed  Google Scholar 

  35. Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, van Rensburg CJ, Swannell AJ, Hawkey CJ. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid suppression trial: ranitidine versus omeprazole for NSAID-associated ulcer treatment (ASTRONAUT) study group. N Engl J Med. 1998;338(11):719–26.

    Article  CAS  PubMed  Google Scholar 

  36. Agrawal NM, Campbell DR, Safdi MA, Lukasik NL, Huang B, Haber MM. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-associated gastric ulcer study group. Arch Intern Med. 2000;160(10):1455–61.

    Article  CAS  PubMed  Google Scholar 

  37. Campbell DR, Haber MM, Sheldon E, Collis C, Lukasik N, Huang B, Goldstein JL. Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine. Am J Gastroenterol. 2002;97(9):2208–14.

    Article  CAS  PubMed  Google Scholar 

  38. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, Yeomans ND. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus misoprostol for NSAID-induced ulcer management (OMNIUM) study group. N Engl J Med. 1998;338(11):727–34.

    Article  CAS  PubMed  Google Scholar 

  39. Bianchi Porro G, Lazzaroni M, Manzionna G, Petrillo M. Omeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer. Aliment Pharmacol Ther. 1998;12(4):355–60.

    Article  CAS  PubMed  Google Scholar 

  40. Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ. 2004;329(7472):948.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Saggioro A, Alvisi V, Blasi A, Dobrilla G, Fioravanti A, Marcolongo R. Misoprostol prevents NSAID-induced gastroduodenal lesions in patients with osteoarthritis and rheumatoid arthritis. Ital J Gastroenterol. 1991;23(3):119–23.

    CAS  PubMed  Google Scholar 

  42. Bocanegra TS, Weaver AL, Tindall EA, Sikes DH, Ball JA, Wallemark CB, Geis GS, Fort JG. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec osteoarthritis study group. J Rheumatol. 1998;25(8):1602–11.

    CAS  PubMed  Google Scholar 

  43. Bianchi Porro G, Lazzaroni M, Petrillo M, Manzionna G, Montrone F, Caruso I. Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment. A double blind placebo controlled study. Ital J Gastroenterol Hepatol. 1998;30(1):43–7.

    CAS  PubMed  Google Scholar 

  44. Robinson M, Mills RJ, Euler AR. Ranitidine prevents duodenal ulcers associated with non-steroidal anti-inflammatory drug therapy. Aliment Pharmacol Ther. 1991;5(2):143–50.

    Article  CAS  PubMed  Google Scholar 

  45. Lanza FL, Chan FK, Quigley EM, Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728–38.

    Article  PubMed  Google Scholar 

  46. Sugano K, Kontani T, Katsuo S, Takei Y, Sakaki N, Ashida K, Mizokami Y, Asaka M, Matsui S, Kanto T, Soen S, Takeuchi T, Hiraishi H, Hiramatsu N. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol. 2012;47(5):540–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Sugano K, Kinoshita Y, Miwa H, Takeuchi T, Esomeprazole NPSG. Randomised clinical trial: esomeprazole for the prevention of nonsteroidal anti-inflammatory drug-related peptic ulcers in Japanese patients. Aliment Pharmacol Ther. 2012;36(2):115–25.

    Article  CAS  PubMed  Google Scholar 

  48. Kurahara K, Matsumoto T, Iida M, Honda K, Yao T, Fujishima M. Clinical and endoscopic features of nonsteroidal anti-inflammatory drug-induced colonic ulcerations. Am J Gastroenterol. 2001;96(2):473–80.

    Article  CAS  PubMed  Google Scholar 

  49. Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, Jury J, Bolla M, Bercik P, Collins SM, Verdu E, Ongini E. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 2011;141(4):1314–22, 1322 e1311-1315.

    Article  CAS  PubMed  Google Scholar 

  50. Duboc H, Rajca S, Rainteau D, Benarous D, Maubert MA, Quervain E, Thomas G, Barbu V, Humbert L, Despras G, Bridonneau C, Dumetz F, Grill JP, Masliah J, Beaugerie L, Cosnes J, Chazouilleres O, Poupon R, Wolf C, Mallet JM, Langella P, Trugnan G, Sokol H, Seksik P. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2013;62(4):531–9.

    Article  CAS  PubMed  Google Scholar 

  51. Washio E, Esaki M, Maehata Y, et al. Proton pump inhibitors increase incidence of nonsteroidal anti-inflammatory drug-induced small bowel injury: a randomized, placebo-controlled trial. Clin Gastroenterol Hepatol. 2016;14(6):809–815.e1.

    Article  CAS  PubMed  Google Scholar 

  52. Niwa Y, Nakamura M, Ohmiya N, Maeda O, Ando T, Itoh A, Hirooka Y, Goto H. Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study. J Gastroenterol. 2008;43(4):270–6.

    Article  CAS  PubMed  Google Scholar 

  53. Fujimori S, Seo T, Gudis K, Ehara A, Kobayashi T, Mitsui K, Yonezawa M, Tanaka S, Tatsuguchi A, Sakamoto C. Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointest Endosc. 2009;69(7):1339–46.

    Article  PubMed  Google Scholar 

  54. Ueda J, Gosho M, Inui Y, Matsuda T, Sakakibara M, Mabe K, Nakajima S, Shimoyama T, Yasuda M, Kawai T, Murakami K, Kamada T, Mizuno M, Kikuchi S, Lin Y, Kato M. Prevalence of Helicobacter pylori infection by birth year and geographic area in Japan. Helicobacter. 2014;19(2):105–10.

    Article  PubMed  Google Scholar 

  55. Tang CL, Ye F, Liu W, Pan XL, Qian J, Zhang GX. Eradication of Helicobacter pylori infection reduces the incidence of peptic ulcer disease in patients using nonsteroidal anti-inflammatory drugs: a meta-analysis. Helicobacter. 2012;17(4):286–96.

    Article  CAS  PubMed  Google Scholar 

  56. Bianchi Porro G, Parente F, Imbesi V, Montrone F, Caruso I. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy. Gut. 1996;39(1):22–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Sakamoto Y, Shimoyama T, Nakagawa S, Mikami T, Fukuda S. Proton pump inhibitor treatment decreases the incidence of upper gastrointestinal disorders in elderly Japanese patients treated with NSAIDs. Intern Med. 2014;53(11):1107–11.

    Article  CAS  PubMed  Google Scholar 

  58. Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol. 2000;151(5):488–96.

    Article  CAS  PubMed  Google Scholar 

  59. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P. Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid. 2014;21(4):221–4.

    Article  PubMed  Google Scholar 

  60. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid. 2010;17(3-4):101–4.

    Article  CAS  PubMed  Google Scholar 

  61. Westermark GT, Fandrich M, Westermark P. AA amyloidosis: pathogenesis and targeted therapy. Annu Rev Pathol. 2015;10:321–44.

    Article  CAS  PubMed  Google Scholar 

  62. Nakagawa M, Sekijima Y, Tojo K, Ikeda S. High prevalence of ATTR amyloidosis in endomyocardial biopsy-proven cardiac amyloidosis patients. Amyloid. 2013;20(2):138–40.

    Article  CAS  PubMed  Google Scholar 

  63. Yamada T. Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med. 1999;37(4):381–8.

    Article  CAS  PubMed  Google Scholar 

  64. Nakamura T. Amyloid A amyloidosis secondary to rheumatoid arthritis: pathophysiology and treatments. Clin Exp Rheumatol. 2011;29(5):850–7.

    PubMed  Google Scholar 

  65. Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356(23):2361–71.

    Article  CAS  PubMed  Google Scholar 

  66. Baba S, Masago SA, Takahashi T, Kasama T, Sugimura H, Tsugane S, Tsutsui Y, Shirasawa H. A novel allelic variant of serum amyloid A, SAA1 gamma: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum Mol Genet. 1995;4(6):1083–7.

    Article  CAS  PubMed  Google Scholar 

  67. Nakamura T, Higashi S, Tomoda K, Tsukano M, Baba S, Shono M. Significance of SAA1.3 allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis. Rheumatology (Oxford). 2006;45(1):43–9.

    Article  CAS  Google Scholar 

  68. Tamura H, Hasegawa K. Jpn J Clin Immunol. 2009;32(1):35–42.

    Article  CAS  Google Scholar 

  69. Gottenberg JE, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B, Combe B, Durbach A, Sibilia J, Dougados M, Mariette X. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum. 2003;48(7):2019–24.

    Article  CAS  PubMed  Google Scholar 

  70. Kuroda T, Wada Y, Kobayashi D, Murakami S, Sakai T, Hirose S, Tanabe N, Saeki T, Nakano M, Narita I. Effective anti-TNF-alpha therapy can induce rapid resolution and sustained decrease of gastroduodenal mucosal amyloid deposits in reactive amyloidosis associated with rheumatoid arthritis. J Rheumatol. 2009;36(11):2409–15.

    Article  CAS  PubMed  Google Scholar 

  71. Nakamura T, Higashi S, Tomoda K, Tsukano M, Shono M. Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol. 2010;29(12):1395–401.

    Article  PubMed  Google Scholar 

  72. Fernandez-Nebro A, Olive A, Castro MC, Varela AH, Riera E, Irigoyen MV, Garcia de Yebenes MJ, Garcia-Vicuna R. Long-term TNF-alpha blockade in patients with amyloid a amyloidosis complicating rheumatic diseases. Am J Med. 2010;123(5):454–61.

    Article  CAS  PubMed  Google Scholar 

  73. Nakamura T, Higashi S, Tomoda K, Tsukano M, Shono M. Effectiveness of etanercept vs cyclophosphamide as treatment for patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Rheumatology (Oxford). 2012;51(11):2064–9.

    Article  CAS  Google Scholar 

  74. Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun. 2004;314(2):363–9.

    Article  CAS  PubMed  Google Scholar 

  75. Hagihara K, Nishikawa T, Sugamata Y, Song J, Isobe T, Taga T, Yoshizaki K. Essential role of STAT3 in cytokine-driven NF-kappaB-mediated serum amyloid A gene expression. Genes Cells. 2005;10(11):1051–63.

    Article  CAS  PubMed  Google Scholar 

  76. Okuda Y, Ohnishi M, Matoba K, Jouyama K, Yamada A, Sawada N, Mokuda S, Murata Y, Takasugi K. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol. 2014;24(1):137–43.

    Article  CAS  PubMed  Google Scholar 

  77. Dember LM, Hawkins PN, Hazenberg BP, Gorevic PD, Merlini G, Butrimiene I, Livneh A, Lesnyak O, Puechal X, Lachmann HJ, Obici L, Balshaw R, Garceau D, Hauck W, Skinner M, Eprodisate for AAATG. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med. 2007;356(23):2349–60.

    Article  CAS  PubMed  Google Scholar 

  78. Ueda M, Ando Y, Nakamura M, Yamashita T, Himeno S, Kim J, Sun X, Saito S, Tateishi T, Bergstrom J, Uchino M. FK506 inhibits murine AA amyloidosis: possible involvement of T cells in amyloidogenesis. J Rheumatol. 2006;33(11):2260–70.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima, Japan

    Tatsuo Fujiwara, Kyoko Katakura & Hiromasa Ohira

Authors
  1. Tatsuo Fujiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kyoko Katakura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiromasa Ohira
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tatsuo Fujiwara .

Editor information

Editors and Affiliations

  1. Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima, Japan

    Hiromasa Ohira

  2. Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan

    Kiyoshi Migita

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Fujiwara, T., Katakura, K., Ohira, H. (2019). Rheumatoid Arthritis and Gastrointestinal Tract Lesions (NSAID Ulcers, Amyloidosis). In: Ohira, H., Migita, K. (eds) Gastrointestinal and Hepatic Manifestations of Rheumatic Diseases. Springer, Singapore. https://doi.org/10.1007/978-981-13-6524-9_7

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-6524-9_7

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-13-6523-2

  • Online ISBN: 978-981-13-6524-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation